News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sucampo Pharmaceuticals, Inc. Submits Marketing Application to Japanese Regulatory Authorities for Amitiza (lubiprostone)


10/7/2010 10:07:25 AM

BETHESDA, Md. & ABBOTT PARK, Ill.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) and Abbott (NYSE:ABT) today announced that Sucampo Pharma Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc., has submitted a marketing application to the Japanese Pharmaceuticals and Medical Devices Agency for approval to market Amitiza® (lubiprostone) 24 mcg for the treatment of chronic idiopathic constipation (CIC).

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES